FOLD
AMICUS THERAPEUTICS, INC.
Key Financials
Gross Profit
$561.3M
↑ 18.1%
Net Income
$-27110000
↑ 51.7%
Revenue
$634.2M
↑ 20.0%
EPS (Diluted)
$-0.09
↑ 50.0%
Total Assets
$949.9M
↑ 21.0%
Operating Income
$32.8M
↑ 31.8%
Shareholders' Equity
$274.2M
↑ 41.3%
Cash & Equivalents
$214.0M
↑ 0.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 3/26/2026 | View on SEC |
| 4 | 3/4/2026 | View on SEC |
| 8-K | 3/3/2026 | View on SEC |
| 144 | 3/2/2026 | View on SEC |
| DEFA14A | 2/23/2026 | View on SEC |
| 10-K | 2/20/2026 | View on SEC |
| 8-K | 2/20/2026 | View on SEC |
| SCHEDULE 13G/A | 2/10/2026 | View on SEC |
| SCHEDULE 13G/A | 2/9/2026 | View on SEC |
| DEFM14A | 2/2/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | FOLD |
| Company Name | AMICUS THERAPEUTICS, INC. |
| CIK | 1178879 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (609) 662-2000 |